Drugs / Recombinant Human Annexin A5
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04850339 Comparator | Dec 2020 → Oct 2021 | — | Annexin Pharmaceuticals AB | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Annexin A5 | “ANXV (Recombinant Human Annexin A5)” NCT04850339 ↗ |
| Known as | ANXV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04850339 ↗ |
| Modality | Protein / enzyme biologic | “ANXV (Recombinant Human Annexin A5)” NCT04850339 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT04850339 ↗ |